The 2026 Maryland Life Science Trend Analysis, produced in partnership with the Maryland Department of Commerce, highlights one of the U.S.’s premier life science hubs, anchored by proximity to major federal research institutions (NIH, FDA, NIST) and a deep talent pool of PhDs and technical workers.
The ecosystem encompasses 1,836 companies in total, including 543 biotech firms, 154 medtech companies, 177 digital health companies, 75 investor companies, and 14 fully integrated pharma companies. Within the biotech segment, R&D services dominates at 263 companies (48%), while therapeutics & diagnostics accounts for 218 firms (40%) and “other” biotech (agrobio, cosmetic, nutraceutical, etc.) makes up the remaining 62 (11%). The leading therapeutic modalities are small molecules (14%), immunotherapy (12%), and a three-way tie between anti-infectives, antibodies, and cell therapy (9% each). Oncology leads the clinical pipeline with 269 assets, followed by infectiology/parasitology (102) and neurology (82). Development activity skews early-stage, with 337 assets in preclinical and 108 in Phase I, versus just 36 in Phase III. A total of 810 assets are available for out-licensing across therapeutics, diagnostics, medical devices, and technologies, with 555 of those being therapeutics — the majority still preclinical (383).
The ownership landscape is predominantly private and independent across most sectors (91–98% for medtech and digital health), with pharma standing as the clear exception at only 43% private versus 36% publicly listed and 21% subsidiary — reflecting the presence of large multinational operations in the state. Company formation peaked in 2017 (55 companies) and 2018 (53 companies), with a visible contraction through 2022–2024 and only 18 companies recorded in 2024, consistent with the broader global slowdown in life science incorporations.
Financing activity shows a market cooling from 2025 into 2026: private equity rounds for life science companies totalled $379M in 2025, dropping to $140M in 2026, with biotech-specific funding following the same trajectory ($248M to $54M). The five-year half-yearly dataset reveals a dramatic peak in 2021 H1 ($565.74M across 24 rounds), a prolonged trough through 2022–2024, and a partial rebound in 2025 H2 ($193.31M across 12 rounds). The top 2025 private equity rounds were led by OncoC4 ($50M Series B), Rapafusyn Pharmaceuticals ($44M Series A), and Alphyn Biologics ($25M Series B). On the M&A front, Maryland’s most notable 2025 deal was the acquisition of Previse by Castle Biosciences ($18.7M), alongside several undisclosed-value transactions — Elixirgen Scientific’s acquisition by Ricoh Company, Oncospace’s acquisition by Sun Nuclear, Previse’s acquisition by Bluesight, and GlycoMimetics’ acquisition by Crescent Biopharma — underscoring continued acquirer interest in Maryland-based diagnostics and oncology assets. IPO activity remained thin but included Ascentage Pharma Group ($126.4M) in 2025, following a stronger 2021 cohort that included NexImmune ($126.5M) and NeoImmuneTech ($103.4M).
Looking ahead, Maryland’s life science sector is supported by its unmatched federal research infrastructure, a dominant R&D services base, and a broad out-licensing pipeline — positioning it as a durable anchor of the U.S. life science map, even as venture financing works through a cyclical downturn.
For more detailed insights, request a free Biotechgate demo.
Download the State of Maryland Trend Analysis 2026 Report for the full PDF.